Patent · US Active

CKIT antibody drug conjugates

US11833215B2 · kind B2 · utility

0Cited by

4References

17Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Tinya Abrams · Richmond, US
Steven Bruce Cohen · San Diego, US
Dylan L. Daniel · San Francisco, US
Catrin Finner · Planegg, DE
Bernhard Hubert Geierstanger · Solana Beach, US
Thomas Huber · Basel, CH
William Mallet · Redwood City, US
Matthew John Meyer · Framingham, US
Weijia Ou · San Diego, US
Siew Ho Schleyer · Emeryville, US
Kathrin Ulrike Tissot-Daguette · Schwanau, DE

Key dates

Filing date	Jun 4, 2020
Grant date	Dec 5, 2023
Priority date	—
Expiry date	Jul 20, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.